A clinician's review of 5-MeO-DMT research for depression

The question

What does the current human research say about 5-MeO-DMT, a short-acting psychedelic, as a possible treatment for depression?

What they did

The authors wrote a review article aimed at primary care clinicians. They summarized what is known about 5-MeO-DMT (also called mebufotenin), a serotonergic psychedelic found in the venom of the Sonoran Desert toad and in some plants. The review covers its safety profile, unanswered questions, and results from early clinical trials.

What they found

The authors report that clinical trials have shown rapid antidepressant effects. They cite top-line data from a phase 2b trial in which 57.5% of participants were in remission from treatment-resistant depression within 8 days. Other phase 2a and 2b trials offered further but still preliminary signs that 5-MeO-DMT may reduce depressive symptoms more than existing drug treatments such as SSRIs. The authors note that safety data suggest low risk in controlled settings, though longer follow-up in people is still needed.

The fine print

This is a review, not new data, and it appears to be a narrative summary rather than a systematic one. The authors themselves note that most studies are early phase with small samples (no more than 193 people), that only two double-blind randomized controlled trials have been run in clinical populations, and that long-term effects are unknown. Top-line results reported by a trial sponsor are not the same as a full peer-reviewed publication. This summary is based on the abstract only.

What it means

Early human research on 5-MeO-DMT for hard-to-treat depression looks promising enough to justify larger trials, but the evidence base is still small, short-term and preliminary.

Evidence grade: Low. This is a narrative review written as a primer for family doctors, summarizing mostly early-phase trials rather than pooling data or testing anything new.

This summary is based on the study’s published abstract.